Michael Farrell - ResMed Insider

ResMed -- USA Stock  

USD 97.94  1.49  1.54%

CEO and Director

Mr. Michael Farrell is Chief Executive Officer and Director of the company. Mr. Farrell was our chief executive officer and a director since March 1, 2013. Before that appointment, he served as our president Americas from May 2011 our senior vice president, strategic business unit sleep from July 2007 to May 2011 our vice president, marketing for the Americas from June 2005 through July 2007 and before that was our vice president, business development. Before joining ResMed in September 2000, Mr. Farrell worked in management consulting, biotechnology, chemicals and steel manufacturing at Arthur D. Little, Genzyme Corporationrationration, Dow Chemical, and BHP Billiton. Mr. Farrell serves on the board of directors of Zimmer Biomet, a multibillion dollar public company that provides implantable musculoskeletal medical devices for patients globally. Mr. Farrell is a member of the Compensation and Management Development committee as well as the Nominating and Governance committee at Zimmer Biomet. Mr. Farrell also serves on the board of directors of the Advanced Medical Technology Association, based in Washington, DC. Mr. Farrell volunteers as a trustee for nonprofit organizations UC San Diego Foundation, Rady Childrens Hospital, the La Jolla Playhouse, and the Museum of Man
Age: 44  CEO Since 2013  MBA    
858-836-5000  http://www.resmed.com
Farrell holds a bachelor of engineering, with firstclass honours, from the University of New South Wales, a master of science in chemical engineering from the Massachusetts Institute of Technology, and an M.B.A. from the MIT Sloan School of Management.

Michael Farrell Latest Insider Activity

Management Efficiency

The company has Return on Asset of 9.1 % which means that on every $100 spent on asset it made $9.1 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 15.29 % implying that it generated $15.29 on every 100 dollars invested.
The company has 1.02 B in debt with debt to equity (D/E) ratio of 50.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. ResMed has Current Ratio of 1.26 demonstrating that it may have difficulties to pay its financial commitments when the payables are due.

Similar Executives

Entity Summary

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. ResMed operates under Medical Instruments Supplies classification in USA and traded on New York Stock Exchange. It employs 6000 people.ResMed (RMD) is traded on New York Stock Exchange in USA. It is located in CALIFORNIA, U.S.A and employs 6,000 people. ResMed is listed under Medical Equipment category by Fama And French industry classification.

ResMed Leadership Team

John Wareham, Director, MBA
Ronald Taylor, Director
Rob Douglas, President
Christopher Roberts, Director, MBA
Gary Pace, Director, Ph.D
Chris Roberts, Director, MBA
Robert Douglas, COO
Agnes Lee, Director
Carol Burt, Director
Rich Sulpizio, Director
Peter Farrell, Chairman, Ph.D
Jim Hollingshead, President, Ph.D
Brett Sandercock, CFO
Ron Taylor, Director
Don Darkin, President
Jack Wareham, Director
Anne Reiser, President
Karen Drexler, Director
Raj Sodhi, President, MBA
David Pendarvis, Executive
Richard Sulpizio, Director
Michael Farrell, CEO, MBA
Richard McHale, President
Donald Darkin, President

Stock Performance Indicators

Did you try this?

Run Fundamentals Comparison Now
   

Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
View All  Next Launch Fundamentals Comparison

Trending Equities

Currently Active Assets on Macroaxis
V   
 NYQ 
Sold over 20 shares of
a day ago
Traded for 124.2
CRM   
 NYQ 
Purchased over 20 shares of
a day ago
Traded for 122.82
MSFT   
 NMS 
Purchased over 30 shares of
a day ago
Traded for 95.0
C   
 NYQ 
Purchased over 40 shares of
a day ago
Traded for 70.0
TWTR   
 NYQ 
Purchased over 90 shares of
a day ago
Traded for 31.91
GM   
 NYQ 
Purchased over 70 shares of
a day ago
Traded for 37.61
Additionally take a look at Your Equity Center. Please also try Commodity Channel Index module to use commodity channel index to analyze current equity momentum.